X-GEN Positions Itself for Growth

X-GEN Pharmaceuticals may be a young company, but its management has decades of experience in the pharmaceutical industry. The management team offers a fresh approach, deeply rooted in tradition, which has prepared the company for significant growth in the coming years.

Established in 2003 and based in Long Island, New York, the privately-owned family company remains committed to the long-standing vision of chairman Dan J. Badia, whose strategic focus is centered on building a lineup of drug products long past patent expiration, but essential to the health care community. The new management team, led by president and chiefexecutive officer Susan Badia, has added an important twist?a greater commitment to broadening its product portfolio.

With a strong product line composed of 50 National Drug Codes, XGEN is positioned to expand its product focus. "We still search out products that are low volume, with few competitors, which have been off patent for several years," said Rob Liles, corporate vice president. "We will continue to add those types of products, but now we also look at drugs nearing patent expiration which open those markets to generic competition. Our experience, partnerships, and resources ready us to thrive in those product markets. The strong relationships we have throughout the supply chain allow us to maximize market share and logistical efficiencies. Additionally, our size, organizational structure, and focused strategies allow us to respond quickly to an everchanging market place."

"We're committed to developing a broader line of products," Liles said. "We select products based on our ability to effectively enhance patient care through the delivery of an affordable generic equivalent." Although the company's typical approach to product development is to file and own Abbreviated New Drug Applications, the strategy of X-GEN incorporates portfolio expansion through the structuring of partnerships which allow the company to leverage its own core competencies as well as those of its partners. "X-GEN has alliances with both US and overseas companies, through licensing and marketing agreements, which capitalize on existing supply chain expertise and facilitate rapid channeling of new products," Liles said. "Ultimately, the goal is to add 3 to 5 products a year to the company portfolio, with a projection of 12 to 15 products within the next 3 years."

Products

Marketed by: X-GEN Pharmaceuticals Inc (Long Island, NY)

Fomepizole Injection 1 g/mL

Indication:

Fomepizole Injection 1 g/mL is an intravenous drug indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis. The product is AP-rated to Jazz Pharmaceuticals' Antizol. The product is supplied as a sterile, preservative-free solution with a latex-free stopper.

Liothyronine Sodium Injection (T₃)

Indication:

Liothyronine Sodium Injection (T3) is an intravenous drug indicated in the treatment of myxedema coma/precoma. The product can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. LiothyronineSodium Injection (T3) is AP-rated to Jones Pharma's Triostat. The product is supplied in a single vial carton containing a1 mL vial at a concentration of 10 mcg/1 mL (base) with a latex-free stopper.

For More Information: www.x-gen.us or 866-390-4411.